An AI-powered model that analyzes electrocardiograms was able to accurately detect COPD early in internal testing and ...
UK pharma major GSK’s Nucala (mepolizumab) has recently received approval in China as add-on maintenance treatment for adults ...
Select your location to view local American Lung Association events and news near you.
GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and the broader label. The company has estimated that among people with COPD who ...
The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled COPD of an eosinophilic phenotype who are already receiving triple therapy ...
AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...
Just how common is COPD? And just how disheartening and confusing can a diagnosis be? These are questions our Senior Contributor Ted Koppel has been grappling with for very many years, and very close ...
Quitting smoking and avoiding vaping may be crucial steps in managing COPD, as these habits expose your lungs to irritants that cause further damage. Quitting may slow the disease’s progression and ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
The COPD therapeutics market presents opportunities in integrated care and digital advancements. Rising disease prevalence ...
Cardiovascular diseases and diabetes are some of the most common coexisting conditions in COPD. Shared risk factors and overlapping physiological processes likely contribute to the high rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results